Compounds > mitomycin
Page last updated: 2024-11-06

mitomycin and Invasiveness, Neoplasm

mitomycin has been researched along with Invasiveness, Neoplasm in 189 studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Research Excerpts

ExcerptRelevanceReference
"This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC)."9.69DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. ( Azawi, N; Dyrskjøt, L; Hansen, E; Jensen, JB; Lindgren, MS; Nielsen, AM, 2023)
"We analyzed the outcomes of a randomized trial demonstrating that in intermediate- to high-risk non-muscle-invasive bladder cancer, mitomycin C and bacillus Calmette-Guérin (BCG) reduced disease relapse compared with BCG alone but was more toxic."9.20Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz ( Alonso, JM; Astobieta, A; Beardo, P; Chantada, V; Fernandez, JM; Gomez, M; Madero, R; Martinez Piñeiro, JA; Martinez-Piñeiro, L; Montesinos, M; Muntañola, P; Ojea, A; Portillo, JA; Rabadan, M; Rodriguez-Molina, J; Solsona, E; Unda, M; Zabala, JA, 2015)
"This paper aims to evaluate the safety and heating efficiency of external deep pelvic hyperthermia combined with intravesical mitomycin C (MMC) as a novel therapy for non-muscle-invasive bladder cancer (NMIBC)."9.19A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. ( Craciunescu, OA; Dewhirst, MW; Inman, BA; Maccarini, PF; Stauffer, PR; Vujaskovic, Z, 2014)
"• To present long-term efficacy data of intravesical thermochemotherapy vs chemotherapy alone with mitomycin-C (MMC) randomly administered to patients with non-muscle-invasive bladder cancer (NMIBC) as an adjuvant treatment after complete transurethral resection."9.15Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). ( Colombo, R; Engelstein, D; Leib, Z; Pavone-Macaluso, M; Salonia, A, 2011)
" Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer."9.15Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. ( Di Stasi, SM; Giurioli, A; Leprini, G; Liberati, E; Masedu, F; Micali, F; Ricci, AR; Valenti, M; Verri, C; Vespasiani, G, 2011)
"To evaluate the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure, including mitomycin (MMC), epirubicin (EPB) and camptothecin (CPT), in the treatment of non-muscle-invasive bladder cancer (NMIBC)."9.15[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer]. ( Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W, 2011)
"The present study compared the therapeutic activity of intravesical BCG with intravesical mitomycin C chemotherapy in patients with non-muscle invasive bladder cancer at intermediate risk of recurrence in a prospective randomised trial."9.13A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. ( Del Nero, A; Mangiarotti, B; Montanari, E; Trinchieri, A, 2008)
" This paper reports our study of the pharmacokinetics of mitomycin C (MMC) administered by intraperitoneal chemohyperthermic perfusion (ICHP) in patients with peritoneal carcinomatosis."9.11Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion. ( Cerretani, D; Cioppa, T; De Stefano, A; Giorgi, G; Marrelli, D; Nastri, G; Nencini, C; Pinto, E; Roviello, F; Urso, R, 2005)
" The relatively new pyrimidine analog gemcitabine (GEM) has exhibited anticancer effect on various solid cancers, such as the advanced bladder cancer."9.05Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. ( Chen, K; Ding, Y; Dong, Z; Gao, K; Li, R; Li, W; Li, Y; Ma, X; Song, J; Wang, Y; Wang, Z; Yang, X, 2020)
"This systematic review and cumulative analysis aimed to explore the efficacy and safety of the combination of intravesical mitomycin C (MMC) plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) patients."8.95Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer. ( Cai, C; Deng, T; Duan, X; Liu, B; Zeng, G; Zhang, T, 2017)
"Intravesical instillations of mitomycin C, epirubicin and BCG are considered as the standard treatment for most patients diagnosed with non-muscle invasive bladder cancer."8.12[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer]. ( Allory, Y; Audenet, F; Leon, P; Loriot, Y; Masson-Lecomte, A; Neuzillet, Y; Pradère, B; Roumiguié, M; Roupret, M; Saint, F; Seisen, T; Traxer, O; Xylinas, E, 2022)
"Due to limited local efficacy of BCG and mitomycin C and the worldwide shortage of BCG, there is a clinical need to develop novel intravesical agents and application forms in order to improve the oncological outcomes in non-muscle invasive bladder cancer (NMIBC)."8.12[Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C]. ( Gakis, G, 2022)
"Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively."7.91Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019)
"To evaluate oncological outcomes after combination intravesical therapy with gemcitabine (GC) and mitomycin C (MMC) in the setting of recurrent non-muscle-invasive bladder cancer (NMIBC) after failure of previous intravesical therapy."7.83Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. ( Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R, 2016)
"To evaluate the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment by urologists members of the French Association of Urology (AFU)."7.83[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment]. ( Colin, P; Comperat, E; Dubosq, F; Houede, N; Larre, S; Masson-Lecomte, A; Mejean, A; Neuzillet, Y; Pignot, G; Puech, P; Roumiguie, M; Roupret, M; Xylinas, E, 2016)
"Starting in 2009 bacillus Calmette-Guérin/electromotive drug administration of mitomycin C was introduced as the standard induction regime in patients with high risk, nonmuscle invasive bladder cancer undergoing bladder conservation."7.83Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. ( Amery, S; Chatterton, K; Gan, C; Khan, MS; O'Brien, T; Thomas, K, 2016)
"Between 2009 and 2011, 20 patients with intermediate and high risk nonmuscle invasive bladder cancer were treated with intravesical mitomycin C (40 mg) combined with regional hyperthermia."7.81Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. ( Crezee, J; de la Rosette, JJ; de Reijke, TM; Geijsen, ED; Koning, CC; Rasch, CR; van Os, RM; Zum Vörde Sive Vörding, PJ, 2015)
"This study sought to determine if the addition of perioperative mitomycin C (MMC) to treatment with bacillus Calmette-Guérin (BCG) after transurethral resection (TURBT) is superior to TURBT plus BCG alone in high grade non-muscle invasive bladder cancer (NMIBC)."7.81Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer. ( Guzzo, TJ; Malkowicz, SB; Pietzak, EJ; Wein, AJ; Weiss, BE, 2015)
"Intravesical BCG immunotherapy and mitomycin C are considered as the standard treatment for non-muscle invasive bladder cancer."7.78[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer]. ( Chartier-Kastler, E; Coloby, P; Larré, S; Mongiat-Artus, P; Neuzillet, Y; Pfister, C; Pignot, G; Rébillard, X; Rouprêt, M; Soulié, M, 2012)
"To analyze the prognostic values of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer who were treated with adjuvant intravesical mitomycin C."7.76Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy. ( Cho, KS; Chung, J; Chung, MK; Joung, JY; Lee, KH; Park, WS; Seo, HK, 2010)
" EMDA of intravesical mitomycin-C (MMC) has been used for treatment of non-muscle invasive bladder cancer (NMIBC) for about a decade on the basis of laboratory studies that demonstrated an enhanced administration rate of MMC into all bladder wall layers after EMDA compared to standard instillation/passive diffusion (PD)."7.75Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. ( Di Stasi, SM; Riedl, C, 2009)
"We retrospectively examined the long-term results of adjuvant chemotherapy with mitomycin-C (MMC) in 50 patients with gastric carcinoma invading the adjacent organs."7.68Adjuvant mitomycin-C prolongs survival time of patients undergoing extensive en bloc resection of carcinoma of the stomach invading the adjacent organs. ( Baba, H; Haraguchi, M; Kakeji, Y; Korenaga, D; Maehara, Y; Orita, H; Sugimachi, K; Watanabe, A, 1990)
"Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy."7.67Mitomycin C in superficial bladder cancer: 24-month follow-up. ( Newling, DW; Richards, B; Robinson, MR; Smith, PH; Somerville, JJ, 1985)
"Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies."6.82Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016)
"Postoperative EMDA with mitomycin is a safe procedure."6.80[Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin]. ( Niedworok, C; Rehme, C; Rübben, H; Vom Dorp, F, 2015)
"Bladder cancer is the second most common urological malignant disease."6.58[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018)
"The treatment of non muscle invasive bladder cancer (NMIBC) continues to be a challenge."6.58Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer. ( Alvarez Casal, M; Domínguez, JL; León-Mata, J; Piñeiro Vázquez, E; Redorta, JP; Sousa Escandón, A; Sousa González, D, 2018)
"To assess the clinical and oncological outcomes of sequential treatment with Bacillus Calmette-Guerin (BCG) and Mitomycin C (MMC) administered with Electromotive Drug Administration (EMDA) in patients with high-risk NMIBC who fail BCG immunotherapy."5.91Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. ( Bravo, A; Breda, A; Gaya, JM; Huguet, J; Palou, J; Robalino, J; Rodríguez Faba, Ó; Sanz Gómez, I; Territo, Á, 2023)
"This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC)."5.69DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. ( Azawi, N; Dyrskjøt, L; Hansen, E; Jensen, JB; Lindgren, MS; Nielsen, AM, 2023)
"Four patients (15."5.56Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. ( Erlich, A; Fleshner, NE; Juvet, T; Krimus, L; Kuk, C; Kulkarni, GS; Lajkosz, K; Mari, A; Wallis, CJ; Zlotta, AR, 2020)
"Optima II ("OPTimized Instillation of Mitomycin for Bladder Cancer Treatment," clinicaltrials."5.51Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer. ( Basak, R; Giannone, K; Hilton, A; Lipman, R; Mueller, D; Smith, AB; Stover, AM; Teal, R; Waheed, M, 2022)
"Ellagic acid (EA) is a polyphenolic compound that can be found as a naturally occurring hydrolysis product of ellagitannins in pomegranates, berries, grapes, green tea and nuts."5.43Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. ( Atzori, MG; Bonanno, E; Ceci, C; Cicconi, R; de Martino, MG; Graziani, G; Lacal, PM; Mattei, M; Miano, R; Scimeca, M; Tentori, L; Vespasiani, G, 2016)
"We analyzed the outcomes of a randomized trial demonstrating that in intermediate- to high-risk non-muscle-invasive bladder cancer, mitomycin C and bacillus Calmette-Guérin (BCG) reduced disease relapse compared with BCG alone but was more toxic."5.20Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz ( Alonso, JM; Astobieta, A; Beardo, P; Chantada, V; Fernandez, JM; Gomez, M; Madero, R; Martinez Piñeiro, JA; Martinez-Piñeiro, L; Montesinos, M; Muntañola, P; Ojea, A; Portillo, JA; Rabadan, M; Rodriguez-Molina, J; Solsona, E; Unda, M; Zabala, JA, 2015)
"We demonstrated in non-muscle-invasive bladder cancer patients with exceptionally frequent recurrences that the risk of long-term recurrence was reduced from 78-80% to 43-45% if one perioperative plus four weekly mitomycin C instillations were followed by monthly bacillus Calmette-Guérin (BCG) instillations for 1 yr instead of alternating instillations of BCG and interferon-α2b."5.20Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon ( Aaltomaa, S; Boström, PJ; Järvinen, R; Kaasinen, E; Kallio, J; Liukkonen, T; Marttila, T; Puolakka, VM; Rintala, E; Seppänen, M; Tuhkanen, K; Vaarala, M; Viitanen, J, 2015)
"This paper aims to evaluate the safety and heating efficiency of external deep pelvic hyperthermia combined with intravesical mitomycin C (MMC) as a novel therapy for non-muscle-invasive bladder cancer (NMIBC)."5.19A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. ( Craciunescu, OA; Dewhirst, MW; Inman, BA; Maccarini, PF; Stauffer, PR; Vujaskovic, Z, 2014)
"Synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly improved locoregional control of bladder cancer, as compared with radiotherapy alone, with no significant increase in adverse events."5.16Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. ( Crundwell, M; Hall, E; Hendron, C; Huddart, RA; Hussain, SA; James, ND; Jenkins, P; Lewis, R; Rawlings, C; Sizer, B; Sreenivasan, T; Tremlett, J; Waters, R, 2012)
"• To present long-term efficacy data of intravesical thermochemotherapy vs chemotherapy alone with mitomycin-C (MMC) randomly administered to patients with non-muscle-invasive bladder cancer (NMIBC) as an adjuvant treatment after complete transurethral resection."5.15Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). ( Colombo, R; Engelstein, D; Leib, Z; Pavone-Macaluso, M; Salonia, A, 2011)
" Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion (PD) of mitomycin and immediate pre-TURBT intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle invasive bladder cancer."5.15Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. ( Di Stasi, SM; Giurioli, A; Leprini, G; Liberati, E; Masedu, F; Micali, F; Ricci, AR; Valenti, M; Verri, C; Vespasiani, G, 2011)
"To evaluate the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure, including mitomycin (MMC), epirubicin (EPB) and camptothecin (CPT), in the treatment of non-muscle-invasive bladder cancer (NMIBC)."5.15[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer]. ( Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W, 2011)
"The present study compared the therapeutic activity of intravesical BCG with intravesical mitomycin C chemotherapy in patients with non-muscle invasive bladder cancer at intermediate risk of recurrence in a prospective randomised trial."5.13A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. ( Del Nero, A; Mangiarotti, B; Montanari, E; Trinchieri, A, 2008)
"We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer."5.11Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004)
" This paper reports our study of the pharmacokinetics of mitomycin C (MMC) administered by intraperitoneal chemohyperthermic perfusion (ICHP) in patients with peritoneal carcinomatosis."5.11Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion. ( Cerretani, D; Cioppa, T; De Stefano, A; Giorgi, G; Marrelli, D; Nastri, G; Nencini, C; Pinto, E; Roviello, F; Urso, R, 2005)
" The relatively new pyrimidine analog gemcitabine (GEM) has exhibited anticancer effect on various solid cancers, such as the advanced bladder cancer."5.05Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. ( Chen, K; Ding, Y; Dong, Z; Gao, K; Li, R; Li, W; Li, Y; Ma, X; Song, J; Wang, Y; Wang, Z; Yang, X, 2020)
"In an effort to decrease recurrence and progression rates in non-muscle-invasive bladder cancer (NMIBC), transurethral resection of a bladder tumor is followed by intravesical instillations using Mitomycin-C (MMC) and Bacillus Calmette-Guérin (BCG)."4.98[Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.] ( Arends, TJH; Coenen, JJMJH; van Valenberg, FJP; Witjes, JA, 2018)
"This systematic review and cumulative analysis aimed to explore the efficacy and safety of the combination of intravesical mitomycin C (MMC) plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) patients."4.95Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer. ( Cai, C; Deng, T; Duan, X; Liu, B; Zeng, G; Zhang, T, 2017)
"Mitomycin C is the gold standard intravesical adjuvant therapy for intermediate-risk non-muscle-invasive bladder cancer (NMIBC)."4.12[Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie]. ( Audenet, F; Brunelle, S; Compérat, E; Houédé, N; Lanz, C; Larré, S; Masson-Lecomte, A; Méjean, A; Neuzillet, Y; Pignot, G; Rollin, P; Roumiguié, M; Rouprêt, M; Xylinas, E, 2022)
"Intravesical instillations of mitomycin C, epirubicin and BCG are considered as the standard treatment for most patients diagnosed with non-muscle invasive bladder cancer."4.12[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer]. ( Allory, Y; Audenet, F; Leon, P; Loriot, Y; Masson-Lecomte, A; Neuzillet, Y; Pradère, B; Roumiguié, M; Roupret, M; Saint, F; Seisen, T; Traxer, O; Xylinas, E, 2022)
"Due to limited local efficacy of BCG and mitomycin C and the worldwide shortage of BCG, there is a clinical need to develop novel intravesical agents and application forms in order to improve the oncological outcomes in non-muscle invasive bladder cancer (NMIBC)."4.12[Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C]. ( Gakis, G, 2022)
"UROMOL racial subtype distributions were similar with class 2a being most common with 10 genes commonly upregulated in AAs compared to EAs including EFEMP1, S100A16, and MCL1 which are associated with progression to muscle-invasive bladder cancer, mitomycin C resistance, and bacillus Calmette-Guérin durability, respectively."4.12Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients. ( Chan, KS; Choi, W; Choi-Kuaea, Y; De Hoedt, AM; Dyrskjøt, L; Eyzaguirre, EJ; Freedland, SJ; Galvan, GC; Kim, M; McConkey, DJ; Shan, Y; Theodorescu, D; Tyler, DS; Widen, S; Williams, SB; You, S; Yu, A, 2022)
"Chemohyperthermia (CHT) with mitomycin C (MMC) is together with Bacillus Calmette-Guérin (BCG), and passive MMC, a treatment option for patients with non muscle-invasive bladder cancer."4.02Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia. ( Corona-laPuerta, M; García-Jarabo, E; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Rodríguez-Antolín, A; Rodríguez-Serrano, A; Villacampa-Aubá, F, 2021)
"Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively."3.91Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019)
"To evaluate oncological outcomes after combination intravesical therapy with gemcitabine (GC) and mitomycin C (MMC) in the setting of recurrent non-muscle-invasive bladder cancer (NMIBC) after failure of previous intravesical therapy."3.83Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. ( Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R, 2016)
"To evaluate the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment by urologists members of the French Association of Urology (AFU)."3.83[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment]. ( Colin, P; Comperat, E; Dubosq, F; Houede, N; Larre, S; Masson-Lecomte, A; Mejean, A; Neuzillet, Y; Pignot, G; Puech, P; Roumiguie, M; Roupret, M; Xylinas, E, 2016)
"Starting in 2009 bacillus Calmette-Guérin/electromotive drug administration of mitomycin C was introduced as the standard induction regime in patients with high risk, nonmuscle invasive bladder cancer undergoing bladder conservation."3.83Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. ( Amery, S; Chatterton, K; Gan, C; Khan, MS; O'Brien, T; Thomas, K, 2016)
"To prospectively evaluate the outcome of combined microwave-induced bladder wall hyperthermia and intravesical mitomycin C instillation (thermochemotherapy) in patients with recurrent non-muscle-invasive bladder cancer."3.81Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? ( Kiss, B; Roth, B; Schneider, S; Thalmann, GN, 2015)
"Between 2009 and 2011, 20 patients with intermediate and high risk nonmuscle invasive bladder cancer were treated with intravesical mitomycin C (40 mg) combined with regional hyperthermia."3.81Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. ( Crezee, J; de la Rosette, JJ; de Reijke, TM; Geijsen, ED; Koning, CC; Rasch, CR; van Os, RM; Zum Vörde Sive Vörding, PJ, 2015)
"This study sought to determine if the addition of perioperative mitomycin C (MMC) to treatment with bacillus Calmette-Guérin (BCG) after transurethral resection (TURBT) is superior to TURBT plus BCG alone in high grade non-muscle invasive bladder cancer (NMIBC)."3.81Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer. ( Guzzo, TJ; Malkowicz, SB; Pietzak, EJ; Wein, AJ; Weiss, BE, 2015)
"The effectiveness of locoregional hyperthermia combined with intravesical instillation of mitomycin C to reduce the risk of recurrence and progression of intermediate- and high-risk nonmuscle-invasive bladder cancer is currently investigated in clinical trials."3.79Novel multisensor probe for monitoring bladder temperature during locoregional chemohyperthermia for nonmuscle-invasive bladder cancer: technical feasibility study. ( Cordeiro, ER; Crezee, H; de la Rosette, J; de Reijke, TM; Geijsen, DE; Hulshof, MC; Schooneveldt, G; Sijbrands, J; Zum Vörde Sive Vörding, PJ, 2013)
"Intravesical BCG immunotherapy and mitomycin C are considered as the standard treatment for non-muscle invasive bladder cancer."3.78[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer]. ( Chartier-Kastler, E; Coloby, P; Larré, S; Mongiat-Artus, P; Neuzillet, Y; Pfister, C; Pignot, G; Rébillard, X; Rouprêt, M; Soulié, M, 2012)
"5 is associated with a decreased risk of tumor recurrence in patients treated with intravesical mitomycin C for nonmuscle invasive bladder cancer."3.77Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. ( Kikuchi, E; Maeda, T; Matsumoto, K; Miyajima, A; Oya, M, 2011)
"To analyze the prognostic values of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer who were treated with adjuvant intravesical mitomycin C."3.76Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy. ( Cho, KS; Chung, J; Chung, MK; Joung, JY; Lee, KH; Park, WS; Seo, HK, 2010)
" EMDA of intravesical mitomycin-C (MMC) has been used for treatment of non-muscle invasive bladder cancer (NMIBC) for about a decade on the basis of laboratory studies that demonstrated an enhanced administration rate of MMC into all bladder wall layers after EMDA compared to standard instillation/passive diffusion (PD)."3.75Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. ( Di Stasi, SM; Riedl, C, 2009)
"We retrospectively examined the long-term results of adjuvant chemotherapy with mitomycin-C (MMC) in 50 patients with gastric carcinoma invading the adjacent organs."3.68Adjuvant mitomycin-C prolongs survival time of patients undergoing extensive en bloc resection of carcinoma of the stomach invading the adjacent organs. ( Baba, H; Haraguchi, M; Kakeji, Y; Korenaga, D; Maehara, Y; Orita, H; Sugimachi, K; Watanabe, A, 1990)
"Of 299 patients who presented with superficial bladder cancer (Ta, T1), 60 were treated by intravesical chemotherapy (Epodyl, methotrexate or mitomycin C)."3.67Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. ( Chisholm, GD; Elton, RA; Hargreave, TB; Newsam, JE; Smith, G, 1986)
"We report 5 cases of invasive squamous cell bladder cancer treated with preoperative mitomycin C and 5-fluorouracil in combination with preoperative external beam radiation therapy (the Nigro regimen), and the subsequent apparent cure of 3 of the 5 patients."3.67A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy. ( Gee, WF; Medina, WD; Mendiondo, OA; Patterson, JM; Ray, EH, 1988)
"Twenty-three patients who were given intravesical Mitomycin C for treatment of superficial bladder cancer have been followed up for a further 12 and 24 months after an initial assessment 5 weeks after completing therapy."3.67Mitomycin C in superficial bladder cancer: 24-month follow-up. ( Newling, DW; Richards, B; Robinson, MR; Smith, PH; Somerville, JJ, 1985)
"Non-muscle invasive bladder cancer (NMIBC) is characterized by a high rate of recurrence and progression, despite surgery and adjuvant therapies."3.01A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer. ( Arrabal-Polo, MÁ; Gómez-Lechuga, P; Jiménez-Moleón, JJ; Martín, MA; Melgarejo-Segura, MT; Morales-Martínez, A; Pareja-Vílchez, M; Yáñez-Castillo, Y, 2023)
" The primary endpoint was recurrence-free survival, and secondary endpoints were progression-free survival and adverse events."2.84Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. ( Masui, S; Onishi, T; Sasaki, T; Shibahara, T; Sugino, Y; Yabana, T, 2017)
"In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy."2.84The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). ( Choudhury, A; Denley, H; Hall, E; Hendron, C; Huddart, R; Hussain, SA; James, N; Lewis, R; Porta, N; West, CM, 2017)
"Non-muscle-invasive bladder cancer (NMIBC) represents a significant global therapeutic challenge, particularly in the era of Bacillus Calmette-Guérin (BCG) shortage."2.82Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. ( Balasubramanian, A; Bolton, D; Gunjur, A; Lawrentschuk, N; Papa, N; Perera, M; Weickhardt, A, 2022)
"Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies."2.82Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016)
"Postoperative EMDA with mitomycin is a safe procedure."2.80[Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin]. ( Niedworok, C; Rehme, C; Rübben, H; Vom Dorp, F, 2015)
" Maintenance chemotherapy started 4-8 weeks later, three courses repeated every 21 days, using 5-FU/CDDP doses above, with MMC reduced to 7 mg/m(2) and administered with the first and third cycles."2.77Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. ( Cunningham, D; Davidson, N; Glynne-Jones, R; Grieve, R; Hurman, DC; Levine, E; Meadows, HM; Plowman, PN; Sebag-Montefiore, D, 2012)
"The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone."2.70A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Moffitt, DD; Peake, D; Wallace, DM, 2001)
"The regimens for colon cancer were, Arm I: mitomycin C [intraoperative portal vein bolus (12 mg/m2) + postoperative, twice weekly and then three times bimonthly for six months intermittent i."2.68Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan. ( , 1995)
"5-FU; and arm III was surgery only."2.68Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. ( Hamano, K; Kato, T; Kodaira, S; Koyama, Y; Ogawa, N; Sakabe, T; Takahashi, T; Tominaga, T; Yasutomi, M, 1996)
"Some 978 patients with colon cancer and 713 patients with rectal cancer were enrolled in the study, 85 (5."2.68[Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer]. ( Hojo, K; Ichihashi, H; Kato, T; Kikuchi, K; Kodaira, S; Kunii, Y; Ogawa, M; Takahashi, T; Tamada, R; Tominaga, T; Yasutomi, M, 1997)
"Vascular invasion and intrahepatic metastasis by hepatocellular carcinoma are important factors predisposing to tumor recurrence."2.67Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. ( Ii, T; Iyobe, T; Izumi, R; Matsui, O; Miyazaki, I; Nonomura, A; Shimizu, K; Yagi, M, 1994)
"Bladder cancer is the second most common urological malignant disease."2.58[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018)
"The treatment of non muscle invasive bladder cancer (NMIBC) continues to be a challenge."2.58Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer. ( Alvarez Casal, M; Domínguez, JL; León-Mata, J; Piñeiro Vázquez, E; Redorta, JP; Sousa Escandón, A; Sousa González, D, 2018)
"As our molecular understanding of bladder cancer continues to advance, more and more novel agents are entering clinical trials across the spectrum of bladder cancer stages."2.58Current Clinical Trials in Non-muscle Invasive Bladder Cancer. ( Batista da Costa, J; Black, PC; Mannas, M; Nykopp, TK, 2018)
"Gallbladder cancer is an aggressive tumor."2.46[Chemotherapy in gallbladder carcinoma]. ( Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R, 2010)
"We successfully treated nodular melanoma and diffuse PAM in a young black woman using a combination of excision with cryotherapy and topical mitomycin C, suggesting that these lesions are amenable to the same types of therapy previously described for white patients."2.43Conjunctival melanoma arising from diffuse primary acquired melanosis in a young black woman. ( Colby, KA; Nagel, DS, 2005)
"In giant fold type scirrhous gastric cancer, the extended operation is favorable."2.39[An extended operation for scirrhous gastric cancer--its significance and procedure]. ( Furukawa, H; Hiratsuka, M; Iwanaga, T; Kameyama, M; Nakamori, S; Nakano, H; Ohigashi, H; Sasaki, Y; Tamura, S; Yasuda, T, 1994)
"In nonmuscle invasive bladder cancer (NMIBC) patients who fail standard intravesical treatment and are unfit or unwilling to undergo a radical cystectomy, radiofrequency (RF)-induced hyperthermia combined with intravesical chemotherapy (RF-CHT) has shown promising results."1.91Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer. ( Brummelhuis, ISG; Crezee, J; Witjes, JA, 2023)
"During the BCG drug shortage, eligible bladder cancer patients were less likely to receive gold standard intravesical BCG with a large variation in treatment patterns between US states."1.91Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage. ( Chun, B; Davies, BJ; Gabriel, N; He, M; Hernandez, I; Jacobs, BL; Jones, C; Vasan, R, 2023)
"To assess the clinical and oncological outcomes of sequential treatment with Bacillus Calmette-Guerin (BCG) and Mitomycin C (MMC) administered with Electromotive Drug Administration (EMDA) in patients with high-risk NMIBC who fail BCG immunotherapy."1.91Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure. ( Bravo, A; Breda, A; Gaya, JM; Huguet, J; Palou, J; Robalino, J; Rodríguez Faba, Ó; Sanz Gómez, I; Territo, Á, 2023)
"Patients with large bladder tumors were evaluated for this study."1.62Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy. ( Buchholz, N; Di Paola, G; Gazzano, G; Hasan, IM; Hendawi, NA; Inneo, V; Raber, M; Tessa, L; Vercesi, A; Viglio, A, 2021)
"Evaluating over 4000 new bladder cancer patients, we found that the QPI programme was associated with low recurrence and accurate staging following the initial transurethral resection of bladder tumour."1.56Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme. ( Ahmad, I; Bhatt, J; Clark, E; Hamid, S; Hasan, R; Hendry, D; Hollins, G; Johnston, A; Mariappan, P; Mitchell, IDC; Nandwani, GM; Padovani, L; Simpson, H; Thomas, BG; Trail, M, 2020)
"Four patients (15."1.56Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. ( Erlich, A; Fleshner, NE; Juvet, T; Krimus, L; Kuk, C; Kulkarni, GS; Lajkosz, K; Mari, A; Wallis, CJ; Zlotta, AR, 2020)
"Topical therapy of nonmuscle-invasive bladder cancer (NMIBC) is based on immunotherapy with Bacillus Calmette-Guerin and chemotherapy administered by passive instillation, but an active drug administration achieves a better concentration of the drugs in the bladder."1.51Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study. ( Carando, R; Cotrufo, S; Ludovico, GM; Zazzara, M, 2019)
"Ellagic acid (EA) is a polyphenolic compound that can be found as a naturally occurring hydrolysis product of ellagitannins in pomegranates, berries, grapes, green tea and nuts."1.43Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. ( Atzori, MG; Bonanno, E; Ceci, C; Cicconi, R; de Martino, MG; Graziani, G; Lacal, PM; Mattei, M; Miano, R; Scimeca, M; Tentori, L; Vespasiani, G, 2016)
"We estimate the annual incidence of bladder cancer in Spain and describe the clinical profile of patients with bladder cancer enrolled in a population based study."1.40Bladder cancer in Spain 2011: population based study. ( Amón Sesmero, JH; Bohorquez Barrientos, A; Castiñeiras Fernández, J; Chantada-Abal, V; Concepción Masip, T; Cózar, JM; de la Rosa-Kehrmann, F; Gómez Rodríguez, A; Gomez-Pascual, JA; Hevia, M; Hidalgo Zabala, E; Lozano, F; Martínez-Ballesteros, C; Medina-Lopez, RA; Miñana, B; Moreno-Sierra, J; Palou, J; Parra Escobar, JL; Pizá Reus, P; Ramos, M; Requena-Tapia, MJ; Ribal, MJ; Rioja Sanz, C; Rodríguez Fernández, E; Serrano, O; Subirá Ríos, J; Unda Urzaiz, M, 2014)
" Adverse effects on the gastrointestinal tract also were lower than in controls (p<0."1.40Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. ( Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014)
"The prognosis of hepatocellular carcinoma (HCC) with macroscopic vascular invasion is extremely poor even after hepatic resection."1.39Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Nitta, H, 2013)
"Ectopic expression of FAVL in bladder cancer cells as well as normal human cells confer an impaired FA pathway and hypersensitivity to Mitomycin C, similar to those found in FA cells, indicating that FAVL elevation may possess the same tumor promotion potential as an impaired FA pathway harbored in FA cells."1.38FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer. ( Dudimah, FD; Fei, P; Panneerselvam, J; Park, HK; Wang, H; Zhang, J; Zhang, P, 2012)
"All of the recurrences in this group had stage Ta grade 1 tumors."1.3810-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. ( Halachmi, S; Moskovitz, B; Moskovitz, M; Nativ, O, 2012)
"Recurrence rates of nonmuscle invasive bladder cancer were obtained from a randomized clinical trial comparing transurethral resection of bladder tumor with or without perioperative mitomycin C."1.38Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. ( Barocas, D; Bramley, T; Bruno, A; Colayco, DC; Globe, DR; Lee, CT; O'Day, K; Oefelein, MG, 2012)
"Using the endometrial cancer cell line EI established in our department, we attempted to establish cisplatin (CDDP)-resistant cell lines by incremental exposure and high concentration exposure methods."1.37Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure. ( Fujitoh, A; Isaka, K; Ito, H; Nishi, H; Sagawa, Y; Yudate, T, 2011)
"Among 11,030 patients with unresectable hepatocellular carcinoma, 8,507 underwent TACE, and 2,523 underwent transarterial infusion therapy with an emulsion of iodized oil and an anticancer agent as initial treatment."1.36Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. ( Arii, S; Ikai, I; Kojiro, M; Kudo, M; Makuuchi, M; Matsuyama, Y; Takayasu, K, 2010)
"Finally, the growth and metastasis of KGN cells injected subcutaneously (s."1.35Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line. ( Imai, M; Muraki, M; Saito, H; Seiki, M; Takahashi, Y; Takamatsu, K, 2008)
"Mitomycin was the most frequently active agent for the superficial part."1.35In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA). ( Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH, 2009)
" The TACE-procedure was carried out in regular intervals using a suspension consisting of a fixed dosage of Mitomycin C (10 mg) and 10-20 ml Lipiodol."1.34[Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences]. ( Düber, C; Herber, S; Junginger, T; Kanzler, S; Kummer, I; Manzl, N; Mönch, C; Otto, G; Pitton, M; Schneider, J; Schuchmann, M, 2007)
"Six patients with gastric cancer, stage IIIA to IV, received intraabdominal cisplatin (CDDP) at laporotomy."1.31[Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion]. ( Kagawa, R; Nakayama, N; Sakata, S; Tada, M; Yamaguchi, T, 2002)
"The median CD4 count at diagnosis of anal cancer was 209 cells/microl (range: 29-380 cells/microl), 5 had prior AIDS defining diagnoses."1.31Treatment of HIV-associated invasive anal cancer with combined chemoradiation. ( Bower, M; Cleator, S; Fife, K; Gazzard, B; Nelson, M; Phillips, R, 2000)
"We treated a case of unresectable gastric cancer in which peritoneal lavage cytology and the primary tumor responded to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection."1.31[A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection]. ( Hattori, T; Hirano, K; Kase, H; Kobayashi, K; Ogawa, M; Teramoto, T; Tokura, N; Washizawa, N, 2000)
"5-Fluorouracil and cisplatin were administered intraperitoneally on postoperative days 1-4, and this was repeated at 4-week intervals."1.31Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. ( Chung, HC; Min, JS; Noh, SH; Roh, JK; Shin, DW; Yoo, CH, 2001)
"Six patients with gastric cancer and two patients with colon cancer underwent these procedures."1.29[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer]. ( Fujimura, T; Fujita, H; Fushida, S; Hirono, Y; Itoh, H; Kaji, M; Kinami, S; Nakagawara, H; Nakai, M; Yonemura, Y, 1995)
"Pancreatic cancer is a disease with essentially no effective treatment."1.29A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Watanabe, M, 1993)
"A new dosage format (MMC-CH) of mitomycin C, which is composed of mitomycin C on activated carbon particles, was efficacious for prevention of peritoneal recurrence of gastric cancer."1.29[Four long-surviving cases of gastric cancer with peritoneal dissemination treated by intraperitoneal administration of mitomycin C adsorbed on activated carbon particles]. ( Hagiwara, A; Oyama, T; Ozaki, K; Sakakibara, T; Sakakura, C; Sasaki, S; Shimotsuma, M; Takahashi, T; Tsujimoto, H, 1993)
"The in vitro drug sensitivity of gastric cancer tissues obtained from 40 patients with advanced cancer was compared in terms of the pathological classifications which were assigned according to the General Rules for the Gastric Cancer Study in Surgery and Pathology in Japan."1.28Relationship between tumor histopathology and in vitro sensitivity to antitumor drugs in gastric cancer. ( Anai, H; Kusumoto, H; Maehara, Y; Sugimachi, K; Takahashi, I; Yoshida, M, 1992)
"Twenty-two patients with hepatocellular carcinoma were treated with transcatheter arterial embolization therapy."1.27[Retrospective study of short survival cases in hepatocellular carcinoma after transcatheter arterial embolization therapy]. ( Fujii, H; Iwai, M; Miyoshi, M; Suyama, Y, 1985)
"Spread of the gastric cancer is multifarious according to its pathological and biophysiological characteristics."1.27[Treatment of gastric cancer based on the pathological and biophysiological aspects of cancer]. ( Nakajima, T; Nishi, M; Ohta, H, 1986)

Research

Studies (189)

TimeframeStudies, this research(%)All Research%
pre-199010 (5.29)18.7374
1990's28 (14.81)18.2507
2000's40 (21.16)29.6817
2010's75 (39.68)24.3611
2020's36 (19.05)2.80

Authors

AuthorsStudies
Gordon, NS1
Baxter, LA1
Goel, A1
Arnold, R1
Kaur, B1
Liu, W1
Pirrie, SJ1
Hussain, S1
Viney, R1
Ford, D1
Zarkar, A2
Wood, MA1
Mitin, T1
Thompson, RF1
James, ND5
Ward, DG1
Bryan, RT1
Carrión, DM1
Gómez Rivas, J1
Aguilera Bazán, A1
Ballesteros Ruiz, C1
Álvarez-Maestro, M1
Ríos González, E1
Martínez-Piñeiro, L3
Zazzara, M2
Nazaraj, A1
Scarcia, M1
Cardo, G1
Carando, R2
Ludovico, GM2
Balasubramanian, A1
Gunjur, A1
Weickhardt, A1
Papa, N1
Bolton, D1
Lawrentschuk, N1
Perera, M1
Rollin, P1
Xylinas, E4
Lanz, C1
Audenet, F2
Brunelle, S1
Compérat, E2
Houédé, N2
Larré, S3
Masson-Lecomte, A3
Pignot, G3
Roumiguié, M3
Méjean, A2
Rouprêt, M7
Neuzillet, Y5
Leon, P1
Saint, F2
Allory, Y1
Loriot, Y1
Pradère, B1
Seisen, T1
Traxer, O1
Gakis, G1
You, S1
Kim, M1
Widen, S1
Yu, A1
Galvan, GC1
Choi-Kuaea, Y1
Eyzaguirre, EJ1
Dyrskjøt, L3
McConkey, DJ1
Choi, W1
Theodorescu, D1
Chan, KS1
Shan, Y1
Tyler, DS1
De Hoedt, AM1
Freedland, SJ1
Williams, SB1
Stover, AM1
Basak, R1
Mueller, D1
Lipman, R1
Teal, R1
Hilton, A1
Giannone, K1
Waheed, M1
Smith, AB2
Lindgren, MS2
Hansen, E1
Azawi, N2
Nielsen, AM1
Jensen, JB2
Melgarejo-Segura, MT1
Morales-Martínez, A1
Yáñez-Castillo, Y1
Arrabal-Polo, MÁ1
Gómez-Lechuga, P1
Pareja-Vílchez, M1
Jiménez-Moleón, JJ1
Martín, MA1
Melgarejo Segura, MT4
Morales Martínez, A4
Yáñez Castillo, Y4
Arrabal Polo, MÁ4
Gómez Lechuga, P3
Pareja Vílchez, M4
Arrabal Martín, M4
Brummelhuis, ISG1
Crezee, J2
Witjes, JA5
Peng, CK1
Sung, WW1
Chen, SL1
Moschini, M2
Salonia, A3
Briganti, A3
Montorsi, F2
Busetto, GM1
Finati, M1
Chirico, M1
Cinelli, F1
D'Altilia, N1
Falagario, UG1
Sanguedolce, F1
Del Giudice, F1
De Berardinis, E1
Ferro, M1
Crocetto, F1
Porreca, A1
Di Gianfrancesco, L2
Calo', B1
Mancini, V1
Bettocchi, C1
Carrieri, G1
Cormio, L1
Chun, B1
He, M1
Jones, C1
Vasan, R1
Gabriel, N1
Jacobs, BL1
Hernandez, I1
Davies, BJ1
Sanz Gómez, I1
Huguet, J2
Bravo, A1
Robalino, J1
Rodríguez Faba, Ó1
Territo, Á1
Gaya, JM1
Palou, J5
Breda, A1
Seiler, R1
Egger, M1
De Menna, M1
Wehrli, S1
Minoli, M1
Radić, M1
Lyatoshinsky, P1
Hösli, R1
Blarer, J1
Abt, D1
Kruithof-de Julio, M1
Laukhtina, E1
Shariat, SF3
Akbulut, F1
Pazir, Y1
Esmeray, A1
Erbin, A1
Ozgor, F1
Sarilar, O1
Prasad, SM1
Huang, WC2
Shore, ND2
Hu, B2
Bjurlin, M1
Brown, G1
Genov, P1
Shishkov, D1
Khuskivadze, A1
Ganev, T1
Marchev, D1
Orlov, I1
Kopyltsov, E1
Zubarev, V1
Nosov, A1
Komlev, D1
Burger, B1
Raju, S2
Meads, A2
Schoenberg, M2
Cotrufo, S1
Faraj, K1
Chang, YH1
Rose, KM1
Habermann, EB1
Etzioni, DA1
Blodgett, G1
Castle, EP1
Humphreys, MR1
Tyson Ii, MD1
Fankhauser, CD1
Teoh, JY1
Mostafid, H1
Li, R1
Li, Y2
Song, J1
Gao, K1
Chen, K1
Yang, X1
Ding, Y1
Ma, X1
Wang, Y2
Li, W1
Wang, Z1
Dong, Z1
Mariappan, P1
Johnston, A1
Padovani, L1
Clark, E1
Trail, M1
Hamid, S1
Hollins, G1
Simpson, H1
Thomas, BG1
Hasan, R1
Bhatt, J1
Ahmad, I1
Nandwani, GM1
Mitchell, IDC1
Hendry, D1
Juvet, T1
Mari, A1
Lajkosz, K1
Wallis, CJ1
Kuk, C1
Erlich, A1
Krimus, L1
Fleshner, NE1
Kulkarni, GS1
Zlotta, AR1
Bue, P1
Blichert-Refsgaard, L1
Sundelin, MO1
González-Padilla, DA1
González-Díaz, A1
Guerrero-Ramos, F1
Rodríguez-Serrano, A1
García-Jarabo, E1
Corona-laPuerta, M1
Rodríguez-Antolín, A1
Villacampa-Aubá, F1
Pierconti, F1
Martini, M1
Fiorentino, V1
Cenci, T1
Capodimonti, S1
Straccia, P1
Sacco, E3
Pugliese, D1
Cindolo, L1
Larocca, LM1
Bassi, PF2
Breton, J1
Bernardeau, S1
Vallée, M1
Pillot, P1
Lebacle, C1
Delpech, PO1
Charles, T1
Biscans, C1
Vallat, A1
Pfister, C2
Irani, J3
Sri, D1
Lee, HJ1
El-Gemmal, S1
Backhouse, C1
Tay, A1
John, B1
Perry, MJ1
Ayres, BE1
Issa, R1
Raber, M1
Buchholz, N1
Vercesi, A1
Hendawi, NA1
Inneo, V1
Di Paola, G1
Tessa, L1
Gazzano, G1
Viglio, A1
Hasan, IM1
Grimberg, DC1
Dudinec, J1
Shah, A1
Inman, BA2
Ourfali, S1
Matillon, X1
Ricci, E1
Fassi-Fehri, H1
Benoit-Janin, M1
Badet, L1
Colombel, M1
Chevli, KK1
Trainer, A1
Saltzstein, D1
Ehrlich, Y1
Raman, JD1
Friedman, B1
D'Anna, R1
Morris, D1
Tyson, M1
Sankin, A1
Kates, M1
Linehan, J1
Scherr, D1
Kester, S1
Verni, M1
Chamie, K1
Karsh, L1
Cinman, A1
Lahiri, S1
Malinowski, M1
Gabai, N1
Seltzer, E1
Hayne, D2
Stockler, M2
McCombie, SP2
Lawrence, N1
Martin, A2
Sengupta, S2
Davis, ID2
Deng, T1
Liu, B2
Duan, X1
Zhang, T1
Cai, C1
Zeng, G1
Gözen, AS1
Umari, P1
Scheitlin, W1
Su, FE1
Akin, Y1
Rassweiler, J1
Bosschieter, J1
Nieuwenhuijzen, JA1
van Ginkel, T1
Vis, AN1
Witte, B1
Newling, D1
Beckers, GMA1
van Moorselaar, RJA1
Ringuette Goulet, C1
Bernard, G1
Chabaud, S1
Couture, A1
Langlois, A1
Neveu, B1
Pouliot, F1
Bolduc, S1
Christoph, F1
König, F1
Lebentrau, S1
Blaschke, S1
Liehr, UB1
Schostak, M1
Unda-Urzaiz, M1
Fernandez-Gomez, JM1
Cozar-Olmo, JM1
Juárez, A1
Böhm, WU1
Koch, R1
Wenzel, S1
Wirth, MP1
Toma, M1
Batura, D1
Hashemzehi, T1
Colemeadow, J1
Tselis, N1
Prott, FJ1
Ott, O1
Weiss, C1
Rödel, C2
Crijnen, J1
De Reijke, TM3
Coenen, JJMJH1
van Valenberg, FJP1
Arends, TJH1
León-Mata, J1
Domínguez, JL1
Redorta, JP1
Sousa González, D1
Alvarez Casal, M1
Sousa Escandón, A1
Piñeiro Vázquez, E1
Chantada-Abal, V2
Chantada-Tirado, C1
Lamas-Díaz, L1
Caramés-Masana, F1
Villegas-Piguave, AD1
Villar-Vázquez, N1
Tapiero, S1
Helfand, A1
Kedar, D1
Yossepowitch, O1
Nadu, A1
Baniel, J1
Lifshitz, D1
Margel, D1
Miernik, A1
Polski, A1
Sibug Saber, M1
Kim, JW1
Berry, JL1
Siracusano, S1
Silvestri, T1
Bassi, S1
Porcaro, AB1
Cerruto, MA1
Talamini, R1
Artibani, W1
Nykopp, TK1
Batista da Costa, J1
Mannas, M1
Black, PC1
Racioppi, M2
Ragonese, M1
Palermo, G1
Santoni, A1
Thariat, J2
Maschi, C1
Herault, J1
Baillif, S1
Lassalle, S1
Peyrichon, ML1
Salleron, J1
Caujolle, JP1
Nitta, H1
Beppu, T1
Imai, K1
Hayashi, H1
Chikamoto, A1
Baba, H2
Huddart, RA2
Hall, E3
Hussain, SA6
Jenkins, P2
Rawlings, C2
Tremlett, J2
Crundwell, M2
Adab, FA1
Sheehan, D1
Syndikus, I1
Hendron, C3
Lewis, R3
Waters, R2
Miñana, B1
Cózar, JM1
Unda Urzaiz, M1
Medina-Lopez, RA1
Subirá Ríos, J1
de la Rosa-Kehrmann, F1
Lozano, F1
Ribal, MJ1
Rodríguez Fernández, E1
Castiñeiras Fernández, J1
Concepción Masip, T1
Requena-Tapia, MJ1
Moreno-Sierra, J1
Hevia, M1
Gómez Rodríguez, A1
Martínez-Ballesteros, C1
Ramos, M1
Amón Sesmero, JH1
Pizá Reus, P1
Bohorquez Barrientos, A1
Rioja Sanz, C1
Gomez-Pascual, JA1
Hidalgo Zabala, E1
Parra Escobar, JL1
Serrano, O1
Cordeiro, ER1
Geijsen, DE1
Zum Vörde Sive Vörding, PJ2
Schooneveldt, G1
Sijbrands, J1
Hulshof, MC1
de la Rosette, J1
Crezee, H1
Stauffer, PR1
Craciunescu, OA1
Maccarini, PF1
Dewhirst, MW1
Vujaskovic, Z1
Zargar, H1
Aning, J1
Ischia, J1
So, A1
Black, P1
Ohsugi, H1
Kitamura, Y1
Manabe, Y1
Masuda, N1
Ito, H2
Mishina, M1
Okuno, H1
Solsona, E1
Madero, R1
Chantada, V1
Fernandez, JM1
Zabala, JA1
Portillo, JA1
Alonso, JM1
Astobieta, A1
Unda, M1
Rabadan, M1
Ojea, A1
Rodriguez-Molina, J1
Beardo, P1
Muntañola, P1
Gomez, M1
Montesinos, M1
Martinez Piñeiro, JA1
Rehme, C1
Niedworok, C1
Rübben, H1
Vom Dorp, F1
Kiss, B1
Schneider, S1
Thalmann, GN1
Roth, B1
Ji, ZQ1
Huang, XE1
Wu, XY1
Liu, J1
Wang, L1
Tang, JH1
Huang, JW1
Hu, BS1
He, X1
Zhao, W1
Zheng, YB1
Lu, LG1
Cockerill, PA1
Knoedler, JJ1
Frank, I1
Tarrell, R1
Karnes, RJ1
Järvinen, R1
Marttila, T1
Kaasinen, E2
Rintala, E1
Aaltomaa, S1
Kallio, J1
Liukkonen, T1
Puolakka, VM1
Seppänen, M1
Tuhkanen, K1
Vaarala, M1
Viitanen, J1
Boström, PJ1
Troussier, I1
Huguet, F1
Servagi-Vernat, S1
Benahim, C1
Khalifa, J1
Darmon, I1
Ortholan, C1
Krebs, L1
Dejean, C1
Fenoglietto, P1
Vieillot, S1
Bensadoun, RJ1
El Hamichi, S1
Messaoudi, R1
Belmalih, M1
Iferkhass, S1
Zerrouk, R1
Reda, K1
Oubaaz, A1
Chalasani, V1
Long, A1
Geijsen, ED1
Koning, CC1
de la Rosette, JJ1
Rasch, CR1
van Os, RM1
Weiss, BE1
Pietzak, EJ1
Wein, AJ1
Malkowicz, SB1
Guzzo, TJ1
Lailler, G1
Rouanne, M1
Lebret, T1
Colin, P1
Dubosq, F1
Puech, P1
Arends, TJ1
Nativ, O3
Maffezzini, M1
de Cobelli, O1
Canepa, G1
Verweij, F1
Moskovitz, B2
van der Heijden, AG1
Gan, C1
Amery, S1
Chatterton, K1
Khan, MS1
Thomas, K1
O'Brien, T1
Stojanović, N1
Brozovic, A1
Majhen, D1
Bosnar, MH1
Fritz, G1
Osmak, M1
Ambriović-Ristov, A1
Onishi, T1
Sugino, Y1
Shibahara, T1
Masui, S1
Yabana, T1
Sasaki, T1
Mbeutcha, A1
Rieken, M1
Rink, M1
Seitz, C1
Lucca, I1
Mathieu, R1
Karakiewicz, PI1
Klatte, T1
Colombo, R3
van Valenberg, H1
Zhuo, C1
Li, X1
Zhuang, H1
Tian, S1
Cui, H1
Jiang, R1
Liu, C1
Tao, R1
Lin, X1
Shen, CY1
Chen, LH1
Lin, YF1
Lai, LC1
Chuang, EY1
Tsai, MH1
Ceci, C1
Tentori, L1
Atzori, MG1
Lacal, PM1
Bonanno, E1
Scimeca, M1
Cicconi, R1
Mattei, M1
de Martino, MG1
Vespasiani, G2
Miano, R1
Graziani, G1
Choudhury, A1
West, CM1
Porta, N1
Denley, H1
Huddart, R1
James, N2
Imai, M1
Muraki, M1
Takamatsu, K1
Saito, H1
Seiki, M1
Takahashi, Y1
Cho, YB1
Lee, WY1
Song, SY1
Choi, SH1
Shin, HJ1
Ahn, KD1
Lee, JM1
Kim, HC1
Yun, SH1
Chun, HK1
Di Stasi, SM3
Riedl, C1
Liberati, E2
Dutto, L1
Verri, C2
Mangiarotti, B1
Trinchieri, A1
Del Nero, A1
Montanari, E1
Hogg, ME1
Popowich, DA1
Wang, EC1
Kiel, KD1
Stryker, SJ1
Halverson, AL1
Gammon, DC1
Dutton, T1
Piperdi, B1
Zybert, J1
Wolfe, SH1
Nguyen, E1
Sbat, D1
Pillarisetty, VG1
Sullivan, M1
Whalen, GF1
Zaki, AA1
Farid, SF1
Rudkin, AK1
Muecke, JS1
Descazeaud, A1
Mignard, JP1
Davin, JL1
Takayasu, K1
Arii, S1
Ikai, I1
Kudo, M1
Matsuyama, Y1
Kojiro, M1
Makuuchi, M1
Yates, DR1
Volpe, A1
Cappa, E1
D'Agostino, D1
Pinto, F1
D'Addessi, A1
Bassi, P1
Aldemir, M1
Canda, AE1
Balbay, MD1
Seo, HK1
Cho, KS1
Chung, J1
Joung, JY1
Park, WS1
Chung, MK1
Lee, KH1
Leib, Z1
Pavone-Macaluso, M1
Engelstein, D1
Abahssain, H1
Afchain, P1
Melas, N1
Ismaili, N1
Rahali, R1
Rabti, HM1
Errihani, H1
Sagawa, Y1
Fujitoh, A1
Nishi, H1
Yudate, T1
Isaka, K1
Maeda, T1
Kikuchi, E1
Matsumoto, K1
Miyajima, A1
Oya, M1
Neulander, EZ1
Kaneti, J1
Valenti, M1
Giurioli, A1
Leprini, G1
Masedu, F1
Ricci, AR1
Micali, F1
Cao, M1
Ma, CK1
Ma, J1
Chen, HG1
Xue, W1
Zigeuner, R1
Boehle, A1
Sylvester, R1
Babjuk, M1
Oosterlinck, W1
Sizer, B1
Sreenivasan, T1
Rocchini, L1
Suardi, N1
Benigni, F1
Colciago, G1
Bettiga, A1
Pellucchi, F1
Maccagnano, C1
Rigatti, P1
Panneerselvam, J1
Park, HK1
Zhang, J1
Dudimah, FD1
Zhang, P1
Wang, H1
Fei, P1
Sebag-Montefiore, D1
Meadows, HM1
Cunningham, D1
Plowman, PN1
Hurman, DC1
Davidson, N1
Grieve, R1
Levine, E1
Glynne-Jones, R1
Halachmi, S1
Moskovitz, M1
Lee, CT1
Barocas, D1
Globe, DR1
Oefelein, MG1
Colayco, DC1
Bruno, A1
O'Day, K1
Bramley, T1
Coloby, P1
Rébillard, X1
Mongiat-Artus, P1
Chartier-Kastler, E1
Soulié, M1
Yang, PT1
Tucker, NA1
Rootman, DB1
Rootman, DS1
McGowan, H1
Chan, CC1
Shields, CL1
Naseripour, M1
Shields, JA1
Eagle, RC1
Kagawa, R1
Nakayama, N1
Yamaguchi, T2
Sakata, S1
Tada, M1
Lorvidhaya, V1
Chitapanarux, I1
Sangruchi, S1
Lertsanguansinchai, P1
Kongthanarat, Y1
Tangkaratt, S1
Visetsiri, E1
Fujiwara, Y1
Taniguchi, H2
Kimura, Y1
Takiguchi, S1
Yasuda, T2
Yano, M1
Monden, M1
Stocken, DD1
Peake, DR1
Glaholm, JG2
Wallace, DM2
Piovesan, LF1
Salvador, J1
Vicente, J1
Villavicencio, H1
Vorob'ëv, GI1
Odariuk, TS1
Orlova, LP1
Nechushkin, MI1
Rybakov, EG1
Colby, KA1
Nagel, DS1
Singh, AD1
Jacques, R1
Rundle, PA1
Rennie, IG1
Mudhar, HS1
Slater, D1
Harland, SJ2
Cerretani, D1
Nencini, C1
Urso, R1
Giorgi, G1
Marrelli, D1
De Stefano, A1
Pinto, E1
Cioppa, T1
Nastri, G1
Roviello, F1
Friedrich, MG2
Pichlmeier, U2
Schwaibold, H1
Conrad, S2
Huland, H2
Evans, CP1
Bessard, A1
Frémin, C1
Ezan, F1
Coutant, A1
Baffet, G1
Herber, S1
Pitton, M1
Mönch, C1
Schneider, J1
Manzl, N1
Kummer, I1
Kanzler, S1
Schuchmann, M1
Junginger, T1
Düber, C1
Otto, G1
Karam, JA1
Lotan, Y1
Ashfaq, R1
Sagalowsky, AI1
Kalsi, J1
Feneley, MR1
Isbarn, H1
Budäus, L1
Balestrazzi, A1
Martone, G1
Pichierri, P1
Tosi, GM1
Caporossi, A1
Marsh, RW1
Agaliotis, D1
Killeen, R1
Takahashi, T4
Kitamura, M1
Arai, K1
Iwasaki, Y1
Fujimura, T2
Yonemura, Y2
Nakagawara, H1
Fujita, H1
Itoh, H1
Hirono, Y1
Kinami, S1
Kaji, M1
Nakai, M1
Fushida, S1
Ohigashi, H2
Ishikawa, O1
Nakamori, S2
Sasaki, Y2
Kabuto, T1
Furukawa, H2
Imaoka, S1
Iwanaga, T2
Hiratsuka, M1
Tamura, S1
Nakano, H1
Kameyama, M1
Tajima, H1
Matsuki, N1
Takeda, T1
Horichi, H1
Kumaki, T1
Shima, K1
Izumi, R1
Shimizu, K1
Iyobe, T1
Ii, T1
Yagi, M1
Matsui, O1
Nonomura, A1
Miyazaki, I1
Sasaki, A1
Furusawa, M1
Tomoda, H1
Seo, Y1
Ohno, S1
Matsukuma, A1
Morita, M1
Kakeji, Y2
Furukawa, T1
Kubota, T1
Watanabe, M1
Kitajima, M1
Hoffman, RM1
Sakakibara, T1
Oyama, T2
Ozaki, K1
Sasaki, S1
Tsujimoto, H1
Sakakura, C2
Shimotsuma, M1
Hagiwara, A2
Koyama, K1
Tanaka, J1
Sato, Y1
Seki, H1
Kato, Y1
Umezawa, A1
Kato, T3
Kodaira, S2
Koyama, Y1
Sakabe, T1
Tominaga, T2
Hamano, K1
Yasutomi, M2
Ogawa, N1
Tohyama, Y1
Kojima, K1
Shirota, Y1
Yasuda, S1
Nakamura, T1
Nihei, Z1
Hirayama, R1
Mishima, Y1
Hojo, K1
Ogawa, M2
Ichihashi, H1
Tamada, R1
Kunii, Y1
Kikuchi, K1
Takei, H1
Iino, Y1
Horiguchi, J1
Maemura, M1
Koibuchi, Y1
Nagaoka, H1
Yokoe, T1
Morishita, Y1
Ayed, M1
Ben Hassine, L1
Ben Slama, R1
Chelbi, N1
Ghozzi, S1
Drissi, H1
Jemni, M1
Chebil, M1
Kobayashi, K2
Fujimoto, S1
Takahashi, M1
Muto, T1
Toyosawa, T1
Smits, G1
Schaafsma, E1
Kiemeney, L1
Caris, C1
Debruyne, F1
Fass, J1
Jansen, M1
Zengel, K1
Reinecke, T1
Asshoff, G1
Schumpelick, V1
Shirasu, M1
Okamoto, K1
Otsuji, E1
Kitamura, K1
Sawai, K1
Yamagishi, H1
Benbow, U1
Maitra, R1
Hamilton, JW1
Brinckerhoff, CE1
Cleator, S1
Fife, K1
Nelson, M1
Gazzard, B1
Phillips, R1
Bower, M1
Washizawa, N1
Tokura, N1
Kase, H1
Hattori, T2
Teramoto, T1
Hirano, K1
Noh, SH1
Yoo, CH1
Chung, HC1
Roh, JK1
Shin, DW1
Min, JS1
Johnston, MR1
Mullen, JB1
Pagura, ME1
Howard, RB1
Moffitt, DD1
Peake, D1
Dunst, J1
Diestelhorst, A1
Heynemann, H1
Schrott, KM1
Sauer, R1
Yachida, S1
Fukushima, N1
Sakamoto, M1
Matsuno, Y1
Kosuge, T1
Hirohashi, S1
Ratto, C1
Ricci, R1
Rossi, C1
Morelli, U1
Vecchio, FM1
Doglietto, GB1
Kusumoto, H1
Maehara, Y2
Yoshida, M1
Takahashi, I1
Anai, H1
Sugimachi, K2
Newling, DW2
Niimoto, M1
Saeki, T1
Toi, M1
Nishiyama, M1
Hirai, T1
Yanagawa, E1
Soloway, MS3
Korenaga, D1
Watanabe, A1
Haraguchi, M1
Orita, H1
Kaibara, N1
Hamazoe, R1
Iitsuka, Y1
Maeta, M1
Koga, S1
Suyama, Y1
Iwai, M1
Fujii, H1
Miyoshi, M1
Nishi, M1
Nakajima, T1
Ohta, H1
Smith, G1
Elton, RA1
Chisholm, GD1
Newsam, JE1
Hargreave, TB1
Abe, R1
Sato, K1
Moriyama, M1
Hardeman, SW1
Perry, A1
Patterson, JM1
Ray, EH1
Mendiondo, OA1
Medina, WD1
Gee, WF1
Urade, M1
Sugiyama, K1
Hasegawa, H1
Hashimoto, T1
Miyata, R1
Matsuda, Y1
Katayama, K1
Yamaguchi, A1
Somerville, JJ1
Richards, B1
Robinson, MR1
Smith, PH1

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence[NCT03558503]Phase 263 participants (Actual)Interventional2018-10-15Completed
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC[NCT03348969]Phase 4120 participants (Actual)Interventional2017-11-01Active, not recruiting
Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375]Phase 2/Phase 3192 participants (Anticipated)Interventional2015-02-28Recruiting
Pilot Study of External Hyperthermia and Intravesical Mitomycin-C To Treat Recurrent Bladder Cancer After Resection and Standard Adjuvant Therapy[NCT00734994]Early Phase 115 participants (Actual)Interventional2008-04-30Completed
The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer[NCT03790384]Phase 4140 participants (Anticipated)Interventional2019-01-15Not yet recruiting
Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869]Phase 3300 participants (Anticipated)Interventional2018-10-26Recruiting
A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)[NCT00384891]Phase 3190 participants (Actual)Interventional2002-02-28Terminated (stopped due to slow accrual)
Intravesical Mitomycin-C With Bladder Wall Hyperthermia in Intermediate and High Risk Non-muscle Invasive Bladder Cancer[NCT03694535]44 participants (Actual)Interventional2012-01-01Completed
Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT- Prospective Controlled Study[NCT02471547]300 participants (Anticipated)Interventional2016-01-31Recruiting
Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.[NCT01149174]Phase 3352 participants (Actual)Interventional1994-01-31Completed
Intravesical Electromotive Mitomycin for High Risk Urothelial Non-muscle Invasive Bladder Cancer After Intravesical Bacillus Calmette-Guérin Failure[NCT04311580]Phase 252 participants (Actual)Interventional2000-01-01Completed
2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer[NCT00024349]Phase 3350 participants (Anticipated)Interventional2001-06-30Completed
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (Study ATEZOBLADDERPRESERVE)[NCT04186013]Phase 239 participants (Anticipated)Interventional2019-09-18Active, not recruiting
Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860]120 participants (Anticipated)Interventional2020-05-26Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Complete Response (CR) Rate for UGN-102 Treatment

To evaluate the tumor ablative effect of UGN-102 in patients with LG NMIBC. CR rate was defined as the percentage of patients with no detectable disease (NDD) as determined by cystoscopy, for cause biopsy, and urine cytology. (NCT03558503)
Timeframe: 3 months after the first instillation of UGN-102

Interventionpercentage of patients (Number)
UGN-10265.1

Mitomycin Area Under the Plasma Concentration-time Curve (AUC)

Mitomycin AUC was assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation) to 6 hours after the first instillation of UGN-102

Interventionng*h/mL (Mean)
UGN-1025.69

Mitomycin Maximum Plasma Concentration (Cmax)

Mitomycin Cmax was assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-102

Interventionng/mL (Mean)
UGN-1022.27

Number of Participants With Post-baseline Clinically Significant (CS) Physical Examination Findings

The number of patients with abnormal, CS physical examination findings post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
UGN-1020

Number of Participants With Post-baseline CS Urology-oriented Physical Examination Findings

The number of patients with abnormal, CS urology-oriented physical examination findings post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
UGN-1022

Number of Participants With Post-baseline PCS Vital Signs Values

The number of patients who met PCS criteria for vital signs parameters post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
UGN-1028

Durable Complete Response (DCR) Rate

To evaluate the durability of response in patients with LG NMIBC who achieve CR. DCR rate was defined as the percentage of patients who maintained CR at the respective time point. (NCT03558503)
Timeframe: 6, 9, and 12 months after the first instillation of UGN-102

Interventionpercentage of patients (Number)
6 months (3 months after CR at the 3-month Visit)9 months (6 months after CR at the 3-month Visit)12 months (9 months after CR at the 3-month Visit)
UGN-10295.173.261.0

Mitomycin Plasma Concentrations

Mitomycin plasma concentrations were assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-102

Interventionng/mL (Mean)
Pre-instillation0.5 hours post-instillation1 hour post-instillation2 hours post-instillation3 hours post-instillation4 hours post-instillation5 hours post-instillation6 hours post-instillation
UGN-10200.750.600.341.881.930.570.32

Number of Participants With Post-baseline Potentially Clinically Significant (PCS) Laboratory Values

The number of patients who met PCS criteria for chemistry or hematology parameters post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Any PCS chemistry valueAny PCS hematology value
UGN-10284

Number of Participants With Treatment-emergent Adverse Events (TEAEs), Study Drug or Procedure Related TEAEs, TEAEs by Maximum Severity, TEAEs Leading to Treatment Discontinuation, and Serious TEAEs.

The number of patients with each type of event will be summarized. Adverse event severity was graded according to Common Terminology Criteria for Adverse Events version 5.0 as follows: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), Grade 5 (fatal). (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Any TEAEsAny study drug or procedure related TEAEsMaximum severity Grade 1Maximum severity Grade 2Maximum severity Grade 3Maximum severity Grade 4Maximum severity Grade 5Any TEAEs leading to treatment discontinuationAny serious TEAEs
UGN-1025740262451165

Median Recurrence Free-survival

Time to first recurrence of cancer in the bladder. (NCT00734994)
Timeframe: Median follow-up 3.18 years

InterventionMonths (Median)
Hyperthermia System, Mitomycin C15.4

Safety and Tolerability

Number of patient treatments stopped due to safety concerns or treatment intolerability. All events below are grade 1/2 toxicity. No grade 3-5 toxicity was observed. (NCT00734994)
Timeframe: During Treatment Phase average 6 weeks

InterventionGrade 1/2 event count (no grade 3+) (Number)
Abdominal painFatigueMyalgiaHeat intoleranceUrethral painChemical cystitisHematuriaBladder spasmWeak urinary streamVaginitisNauseaConstipationSwellingPruritisRashBruisingFlushingDizzinessConfusionAnxietyExtrapyramidal symptomsUrinary Tract InfectionHypertension
Mitomycin C With Hyperthermia52116432112143211211123

Reviews

28 reviews available for mitomycin and Invasiveness, Neoplasm

ArticleYear
Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
    World journal of urology, 2022, Volume: 40, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Female; Humans; Male; Mitomycin;

2022
A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:4

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Humans; Mitomycin; Neoplasm

2023
Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.
    Current opinion in urology, 2020, Volume: 30, Issue:3

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Chemotherapy, Adjuvant; Huma

2020
Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
    BMC urology, 2020, Jul-13, Volume: 20, Issue:1

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Deoxycyt

2020
BCG + Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned.
    BJU international, 2017, Volume: 119 Suppl 5

    Topics: Administration, Intravesical; Australia; BCG Vaccine; Clinical Trials, Phase III as Topic; Disease-F

2017
Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder Cancer.
    Scientific reports, 2017, 06-09, Volume: 7, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Female; Humans; Male; Middle Aged

2017
[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer].
    Aktuelle Urologie, 2018, Volume: 49, Issue:2

    Topics: Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Humans; Hyperthermia, Induced; Mitomy

2018
[Radiochemotherapy for invasive bladder cancer : An update].
    Der Urologe. Ausg. A, 2018, Volume: 57, Issue:6

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Chemoradio

2018
Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
    Expert opinion on emerging drugs, 2018, Volume: 23, Issue:2

    Topics: Administration, Intravesical; Animals; Antineoplastic Agents; BCG Vaccine; Disease Progression; Drug

2018
[Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.]
    Archivos espanoles de urologia, 2018, Volume: 71, Issue:4

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Combined Modality Therapy; Forecasting; H

2018
Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer.
    Archivos espanoles de urologia, 2018, Volume: 71, Issue:4

    Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Ne

2018
[Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.]
    Archivos espanoles de urologia, 2018, Volume: 71, Issue:4

    Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Drug Therapy, Combination; Humans;

2018
[Nonmuscle invasive bladder cancer : Efficacy of electromotive drug administration].
    Der Urologe. Ausg. A, 2018, Volume: 57, Issue:9

    Topics: Administration, Intravesical; Drug Administration Routes; Humans; Iontophoresis; Mitomycin; Neoplasm

2018
Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Current urology reports, 2018, Oct-24, Volume: 19, Issue:12

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibodies, Monoclonal; Antibodies, Monoclonal

2018
Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.
    Nature reviews. Urology, 2014, Volume: 11, Issue:4

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Resistance, Neoplasm; Drug Therapy,

2014
Radiofrequency-induced thermo-chemotherapy effect (RITE) for non muscle invasive bladder cancer treatment: current role and perspectives.
    Urologia, 2016, Oct-04, Volume: 83, Issue:Suppl 2

    Topics: Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasiveness; Urinar

2016
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
    Oncotarget, 2016, Dec-13, Volume: 7, Issue:50

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol

2016
[Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 5

    Topics: Adjuvants, Immunologic; Age Factors; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Si

2008
[Bacillus of Calmette-Guérin immunotherapy: which protocol?].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 5

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Clin

2008
Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2008, Volume: 80, Issue:4

    Topics: Antibiotics, Antineoplastic; Electrochemotherapy; Humans; Mitomycin; Neoplasm Invasiveness; Urinary

2008
Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options.
    BJU international, 2010, Volume: 106, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystec

2010
[Chemotherapy in gallbladder carcinoma].
    Presse medicale (Paris, France : 1983), 2010, Volume: 39, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxyc

2010
Management of muscle invasive bladder cancer--British approaches to organ conservation.
    Seminars in radiation oncology, 2005, Volume: 15, Issue:1

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2005
Conjunctival melanoma arising from diffuse primary acquired melanosis in a young black woman.
    Cornea, 2005, Volume: 24, Issue:3

    Topics: Administration, Topical; Adult; Antibiotics, Antineoplastic; Black People; Combined Modality Therapy

2005
Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Expert opinion on drug delivery, 2008, Volume: 5, Issue:1

    Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Hu

2008
[Mechanism of neoplasm metastasis and treatment strategy].
    Nihon Geka Gakkai zasshi, 1995, Volume: 96, Issue:8

    Topics: Humans; Immunotoxins; Mitomycin; Neoplasm Invasiveness; Neoplasm Metastasis; Peritoneal Neoplasms; S

1995
[An extended operation for scirrhous gastric cancer--its significance and procedure].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:14

    Topics: Adenocarcinoma, Scirrhous; Cholecystectomy; Colectomy; Gastrectomy; Humans; Infusions, Parenteral; L

1994
Radiochemotherapy for T1G3 bladder cancer.
    Frontiers of radiation therapy and oncology, 2002, Volume: 36

    Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined

2002

Trials

45 trials available for mitomycin and Invasiveness, Neoplasm

ArticleYear
The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: Interim analysis of the PRECAVE randomized clinical trial.
    Archivos espanoles de urologia, 2021, Volume: 74, Issue:9

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cystectomy; Humans; Mitomycin; Neoadjuvan

2021
Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.
    The Journal of urology, 2022, Volume: 208, Issue:3

    Topics: Administration, Intravesical; Adult; Antibiotics, Antineoplastic; Female; Flatulence; Humans; Male;

2022
DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-10, Volume: 41, Issue:2

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Invasiveness;

2023
Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. Letter.
    The Journal of urology, 2023, Volume: 209, Issue:5

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoadjuvant Therapy; N

2023
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    European urology, 2023, Volume: 84, Issue:4

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoadjuvant Therapy; N

2023
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
    BMC urology, 2023, May-11, Volume: 23, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Humans; Mitomycin; Neoplasm Invasiveness; Neop

2023
Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    European urology, 2023, Volume: 84, Issue:5

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Mitomycin; Neoplasm Invasiveness;

2023
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    The Journal of urology, 2023, Volume: 210, Issue:4

    Topics: Administration, Intravesical; Female; Humans; Male; Mitomycin; Neoplasm Invasiveness; Neoplasm Recur

2023
The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
    European urology, 2020, Volume: 78, Issue:6

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy;

2020
[Single, immediate postoperative intra-vesical instillation (SI) compared to a single preoperative intra-vesical instillation of mitomycin C in non-muscle invasive bladder cancer (NMIBC). Phase II randomized trial].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2021, Volume: 31, Issue:2

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Female; Humans; Male; Mitomycin; Neoplasm

2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    The Journal of urology, 2022, Volume: 207, Issue:1

    Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Hy

2022
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    European urology, 2018, Volume: 73, Issue:2

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy;

2018
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    BMC cancer, 2018, Dec-06, Volume: 18, Issue:1

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Female; Follow-Up Studies; Humans;

2018
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
    International journal of radiation oncology, biology, physics, 2013, Oct-01, Volume: 87, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2013
A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2014, Volume: 30, Issue:3

    Topics: Aged; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Pe

2014
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
    European urology, 2015, Volume: 67, Issue:3

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem

2015
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
    European urology, 2015, Volume: 67, Issue:3

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem

2015
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
    European urology, 2015, Volume: 67, Issue:3

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem

2015
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz
    European urology, 2015, Volume: 67, Issue:3

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chem

2015
[Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].
    Der Urologe. Ausg. A, 2015, Volume: 54, Issue:2

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Electrochemother

2015
Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial.
    Oncology, 2015, Volume: 89, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon
    European urology, 2015, Volume: 68, Issue:4

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P

2015
BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
    BMC cancer, 2015, May-27, Volume: 15

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Clinical Protocols; Combined

2015
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    European urology, 2016, Volume: 69, Issue:6

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine

2016
Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer.
    BJU international, 2017, Volume: 119, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Cystectomy;

2017
The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
    British journal of cancer, 2017, Feb-28, Volume: 116, Issue:5

    Topics: Adult; Aged; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm

2017
A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2008, Volume: 80, Issue:4

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A

2008
Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).
    BJU international, 2011, Volume: 107, Issue:6

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Epidemiolog

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:9

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

2011
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:5

    Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplas

2011
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
    The New England journal of medicine, 2012, Apr-19, Volume: 366, Issue:16

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv

2012
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
    The New England journal of medicine, 2012, Apr-19, Volume: 366, Issue:16

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv

2012
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
    The New England journal of medicine, 2012, Apr-19, Volume: 366, Issue:16

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv

2012
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
    The New England journal of medicine, 2012, Apr-19, Volume: 366, Issue:16

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv

2012
Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
    European urology, 2012, Volume: 62, Issue:5

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cell Prol

2012
Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 104, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel

2012
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
    International journal of radiation oncology, biology, physics, 2003, Apr-01, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B

2003
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
    British journal of cancer, 2004, Jun-01, Volume: 90, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit

2004
Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Area Under Curve; Chemotherapy, Cancer, Regional Perfusion

2005
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    European urology, 2007, Volume: 52, Issue:4

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Ca

2007
[Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:5

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci

2008
[Evaluation of intraoperative peritoneal cytology and intraperitoneal chemotherapy using CDDP combined with MMC for gastric carcinomatous peritonitis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Female; Human

1995
Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
    Japanese journal of clinical oncology, 1995, Volume: 25, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis

1995
Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 1994, Volume: 20, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization,

1994
Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.
    American journal of clinical oncology, 1996, Volume: 19, Issue:4

    Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

1996
[Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi

1997
Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.
    Urology, 1998, Volume: 52, Issue:6

    Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Dise

1998
[Results of intraperitoneal active charcoal-mitomycin C therapy of stomach carcinoma with serosa invasion].
    Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 1998, Volume: 115

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Charcoal; Chemotherapy, Cancer, Regional P

1998
A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:7

    Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2001
Prospective randomized controlled study on bestatin in resectable gastric cancer--third report.
    The Japanese journal of surgery, 1990, Volume: 20, Issue:2

    Topics: Adjuvants, Immunologic; Aminopeptidases; Antibiotics, Antineoplastic; Antineoplastic Combined Chemot

1990
Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer.
    Hepato-gastroenterology, 1989, Volume: 36, Issue:2

    Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials as Topic; Combined Modality Therapy

1989

Other Studies

116 other studies available for mitomycin and Invasiveness, Neoplasm

ArticleYear
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study.
    BJU international, 2022, Volume: 129, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemoradiotherapy; Cli

2022
Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Urologia internationalis, 2023, Volume: 107, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Immunotherapy; Mitomycin;

2023
[Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2022, Volume: 32, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine

2022
[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2022, Volume: 32, Issue:5

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Epirubicin; Female; Humans;

2022
[Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C].
    Aktuelle Urologie, 2022, Volume: 53, Issue:2

    Topics: Administration, Intravesical; BCG Vaccine; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasi

2022
Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients.
    Urologic oncology, 2022, Volume: 40, Issue:9

    Topics: BCG Vaccine; Black or African American; Extracellular Matrix Proteins; Humans; Mitomycin; Neoplasm I

2022
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Urologic oncology, 2023, Volume: 41, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2023
Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2023, Volume: 40, Issue:1

    Topics: Combined Modality Therapy; Epirubicin; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasivene

2023
Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10

    Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Humans; Mitomycin; Neoplasm Invas

2023
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
    World journal of urology, 2023, Volume: 41, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Conser

2023
Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage.
    Urology, 2023, Volume: 177

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Humans; Medicare; Mitomycin

2023
Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
    Clinical genitourinary cancer, 2023, Volume: 21, Issue:4

    Topics: Administration, Intravesical; Aged; BCG Vaccine; Humans; Immunotherapy; Mitomycin; Neoplasm Invasive

2023
The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
    Urologia, 2023, Volume: 90, Issue:4

    Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Hum

2023
Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
    Urologia internationalis, 2019, Volume: 103, Issue:3

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Electrochemotherapy; Female; Humans

2019
Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
    The Canadian journal of urology, 2019, Volume: 26, Issue:5

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A

2019
Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    European urology, 2020, Volume: 78, Issue:4

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cystectom

2020
Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Urologic oncology, 2020, Volume: 38, Issue:11

    Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Female; Humans; Iontophoresi

2020
Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia.
    Urologic oncology, 2021, Volume: 39, Issue:1

    Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Chemother

2021
The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
    Urologic oncology, 2021, Volume: 39, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineop

2021
Cystectomy outcomes in patients who have failed Radiofrequency-induced Thermo-chemotherapeutic Effect Mitomycin-C (RITE-MMC) treatment for high-risk non-muscle invasive bladder cancer (HRNMIBC)-Does it complicate surgery and adversely impact oncological o
    Urologic oncology, 2021, Volume: 39, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Cystectomy;

2021
Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy.
    Urologia internationalis, 2021, Volume: 105, Issue:3-4

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, Ad

2021
Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
    Urologic oncology, 2021, Volume: 39, Issue:8

    Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Female; Follow-Up Stud

2021
Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer.
    European urology focus, 2022, Volume: 8, Issue:5

    Topics: BCG Vaccine; Humans; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Retros

2022
Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2017, Jun-30, Volume: 89, Issue:2

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined

2017
Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery.
    Biomaterials, 2017, Volume: 145

    Topics: Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Human Umbilical Vein Endothelial Cel

2017
Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer.
    Actas urologicas espanolas, 2018, Volume: 42, Issue:2

    Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona

2018
[Development and treatment of localized/systemic BCGitis : Retrospective studies in direct comparison to mitomycin C].
    Der Urologe. Ausg. A, 2018, Volume: 57, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2018
A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer.
    International urology and nephrology, 2018, Volume: 50, Issue:6

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Guidelin

2018
Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
    Urology, 2018, Volume: 118

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine

2018
Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia.
    Clinical & experimental ophthalmology, 2019, Volume: 47, Issue:2

    Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Corneal Disea

2019
Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer.
    The Canadian journal of urology, 2018, Volume: 25, Issue:5

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Age Factors; Aged; Aged, 80 and over; A

2018
Management of Invasive Squamous Cell Carcinomas of the Conjunctiva.
    American journal of ophthalmology, 2019, Volume: 200

    Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctival

2019
Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.
    World journal of surgery, 2013, Volume: 37, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

2013
Bladder cancer in Spain 2011: population based study.
    The Journal of urology, 2014, Volume: 191, Issue:2

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Comorbidi

2014
Novel multisensor probe for monitoring bladder temperature during locoregional chemohyperthermia for nonmuscle-invasive bladder cancer: technical feasibility study.
    Journal of endourology, 2013, Volume: 27, Issue:12

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Body Temperature; Equipment Design; Feasi

2013
[Efficacy of prophylactic intravesical mitomycin C in patients with non-muscle-invasive bladder cancer].
    Hinyokika kiyo. Acta urologica Japonica, 2014, Volume: 60, Issue:8

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Mitomycin;

2014
Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?
    International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:2

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; F

2015
Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brucea; Cantharidin;

2014
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
    BJU international, 2016, Volume: 117, Issue:3

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol

2016
[Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2015, Volume: 19, Issue:2

    Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell

2015
Bilateral enucleation avoided by excision with mitomycin C for bilateral infiltrating conjunctival squamous cell carcinoma in a girl with xeroderma pigmentosum.
    Journal francais d'ophtalmologie, 2015, Volume: 38, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Child; Combined Modality Therapy; Conjunctival Neop

2015
Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
    The Journal of urology, 2015, Volume: 194, Issue:5

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined

2015
Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
    The Canadian journal of urology, 2015, Volume: 22, Issue:4

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P

2015
[Assessment of the optimization of the conditions of mitomycin C intravesical instillation completion in the setting of non-muscle invasive bladder cancer treatment].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2016, Volume: 26, Issue:2

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drinking Water; Humans; Mitomycin; Neopla

2016
[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2016, Volume: 26, Issue:3

    Topics: Administration, Intravesical; Combined Modality Therapy; France; Health Care Surveys; Humans; Mitomy

2016
Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    The Journal of urology, 2016, Volume: 195, Issue:6

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Alkylating Agents; Cystoscopy; Drug Ther

2016
Integrin αvβ3 expression in tongue squamous carcinoma cells Cal27 confers anticancer drug resistance through loss of pSrc(Y418).
    Biochimica et biophysica acta, 2016, Volume: 1863, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cisplatin; Dasatin

2016
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
    Urologic oncology, 2016, Volume: 34, Issue:11

    Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; BCG Vaccine; Biomarkers; C-Reactive Protein; Ca

2016
Mitomycin C treatment induces resistance and enhanced migration via phosphorylated Akt in aggressive lung cancer cells.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Syn

2016
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.
    Nutrients, 2016, Nov-22, Volume: 8, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-H1 A

2016
Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line.
    BMC cancer, 2008, Nov-04, Volume: 8

    Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Disease Progression; Female; Gr

2008
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antit

2009
Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    World journal of urology, 2009, Volume: 27, Issue:3

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Electrochemotherapy; Humans; Mitomycin; N

2009
HIV and anal cancer outcomes: a single institution's experience.
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:5

    Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan

2009
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Jul-01, Volume: 66, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality

2009
Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
    Cornea, 2009, Volume: 28, Issue:9

    Topics: Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy

2009
Topical mitomycin following cryotherapy for treatment of recurrent ocular surface melanoma.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2009, Volume: 44, Issue:5

    Topics: Administration, Topical; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy;

2009
[Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2009, Volume: 19, Issue:9

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Fran

2009
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular;

2010
Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach.
    Urologia internationalis, 2010, Volume: 85, Issue:3

    Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female;

2010
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladd
    European urology, 2010, Volume: 58, Issue:2

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2010
Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
    Urology, 2010, Volume: 76, Issue:2

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemother

2010
Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2011, Volume: 32, Issue:2

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship,

2011
Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    The Journal of urology, 2011, Volume: 185, Issue:3

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; H

2011
Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).
    BJU international, 2011, Volume: 107, Issue:10

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Humans; Hyperthermia, Induced; Mitomycin;

2011
[European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract].
    Actas urologicas espanolas, 2012, Volume: 36, Issue:1

    Topics: BCG Vaccine; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Diagnostic Ima

2012
FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer.
    Cell cycle (Georgetown, Tex.), 2012, Aug-01, Volume: 11, Issue:15

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; Fanconi Anemia; Fanconi Anemi

2012
10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer.
    Future oncology (London, England), 2012, Volume: 8, Issue:8

    Topics: Administration, Intravesical; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Foll

2012
Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
    The Journal of urology, 2012, Volume: 188, Issue:6

    Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Cost of Illness; Humans; Mitomycin; Neopl

2012
[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2012, Volume: 22, Issue:15

    Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Huma

2012
Pagetoid spread of sebaceous cell carcinoma to the cornea.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2012, Volume: 47, Issue:6

    Topics: Adenocarcinoma, Sebaceous; Administration, Topical; Antibiotics, Antineoplastic; Biopsy; Conjunctiva

2012
Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma.
    Ophthalmology, 2002, Volume: 109, Issue:11

    Topics: Adenocarcinoma, Sebaceous; Administration, Topical; Aged; Aged, 80 and over; Antibiotics, Antineopla

2002
[Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:11

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin

2002
[Two advanced gastric cancer patients who showed malignant ileus soon after administration of combination therapy of preoperative intra-peritoneal chemotherapy and gastrectomy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modal

2003
Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup.
    The Journal of urology, 2004, Volume: 172, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Endo

2004
[Prognosis of epidermoid anal carcinoma regression after conservative treatment].
    Voprosy onkologii, 2004, Volume: 50, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc

2004
Neoadjuvant topical mitomycin C chemotherapy for conjunctival and corneal intraepithelial neoplasia.
    Eye (London, England), 2006, Volume: 20, Issue:9

    Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Conjunctival Neoplasms; Cornea; Humans; Male;

2006
Electromotive drug delivery and bladder cancer.
    The Lancet. Oncology, 2006, Volume: 7, Issue:1

    Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Disease Progression; Electric Stimulation The

2006
Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder c
    European urology, 2007, Volume: 52, Issue:4

    Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Huma

2007
MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
    Journal of cellular physiology, 2007, Volume: 212, Issue:2

    Topics: Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans;

2007
[Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences].
    Zentralblatt fur Chirurgie, 2007, Volume: 132, Issue:4

    Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Cause of Death; Chemoembolization, The

2007
Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Urology, 2007, Volume: 70, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma, Transitio

2007
Corneal invasion of ocular surface squamous neoplasia after clear corneal phacoemulsification: in vivo confocal microscopy analysis.
    Journal of cataract and refractive surgery, 2008, Volume: 34, Issue:6

    Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Cornea; Corneal Diseases; Eye Neoplasms; Humans; Mal

2008
Treatment of invasive squamous cell carcinoma complicating anal Buschke-Löwenstein tumor: a case history.
    Cutis, 1995, Volume: 55, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Anus Neoplasms; Carcinoma, Squamous C

1995
[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined

1995
[Promotion of hematogenous metastasis in relation to endothelial cell injury by treatment with anticancer drugs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Animals; Antineoplastic Agents; Cell Division; Doxorubicin; Endothelium; Fluorouracil; Humans; Mitom

1994
[A case of cutaneous and brain metastasis of gastric carcinoma, treated effectively by chemotherapy with CDDP, MMC, etoposide and 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:15

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ne

1994
[Effect of adjuvant chemotherapy for patients with early gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

1994
A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice.
    Cancer research, 1993, Jul-01, Volume: 53, Issue:13

    Topics: Animals; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopl

1993
[Four long-surviving cases of gastric cancer with peritoneal dissemination treated by intraperitoneal administration of mitomycin C adsorbed on activated carbon particles].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Carbon; Chemotherapy, Adjuvant; Delayed-Action Preparations; Female; Ga

1993
Experience in twenty patients with carcinoma of hilar bile duct treated by resection, targeting chemotherapy and intracavitary irradiation.
    Surgery, gynecology & obstetrics, 1993, Volume: 176, Issue:3

    Topics: Adult; Aged; Bile Duct Neoplasms; Brachytherapy; Chemotherapy, Adjuvant; Cobalt Radioisotopes; Combi

1993
[A case of nonresectable advanced gastric cancer responding to combined chemotherapy with 5'-DFUR, CDDP, and MMC].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Flox

1996
Angiogenesis and stromal fibronectin expression in invasive breast carcinoma.
    International journal of oncology, 1998, Volume: 12, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp

1998
[Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1998, Volume: 8, Issue:2

    Topics: Actuarial Analysis; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antin

1998
[Clinical result of intraperitoneal hyperthermic chemoperfusion for gastric cancer with serosal invasion to prevent peritoneal recurrence].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Hyperthermia,

1998
[Preoperative chemotherapy targeting lymphatic apparatus in the peritoneal cavity of gastric cancer patients with serosal invasion using mitomycin C bound to activated carbon particles].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:4

    Topics: Adult; Aged; Carbon; Female; Humans; Infusions, Parenteral; Lymphatic System; Male; Middle Aged; Mit

1999
Selective inhibition of collagenase-1, gelatinase A, and gelatinase B by chemotherapeutic agents.
    Annals of the New York Academy of Sciences, 1999, Jun-30, Volume: 878

    Topics: Acetylcysteine; Antineoplastic Agents; Carboplatin; Cisplatin; Doxorubicin; Gelatinases; Humans; Mat

1999
Treatment of HIV-associated invasive anal cancer with combined chemoradiation.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Fl

2000
[A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci

2000
Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
    Oncology, 2001, Volume: 60, Issue:1

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth

2001
Validation of an orthotopic model of human lung cancer with regional and systemic metastases.
    The Annals of thoracic surgery, 2001, Volume: 71, Issue:4

    Topics: Analysis of Variance; Animals; Antineoplastic Agents; Carcinoma, Large Cell; Cisplatin; Disease Mode

2001
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
    The British journal of surgery, 2002, Volume: 89, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2002
Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer.
    Diseases of the colon and rectum, 2002, Volume: 45, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2002
Relationship between tumor histopathology and in vitro sensitivity to antitumor drugs in gastric cancer.
    Anti-cancer drugs, 1992, Volume: 3, Issue:1

    Topics: Aclarubicin; Adenocarcinoma; Antineoplastic Agents; Carbazilquinone; Cisplatin; Doxorubicin; Drug Sc

1992
Organ conservation in bladder cancer.
    Progress in clinical and biological research, 1991, Volume: 370

    Topics: Administration, Intravesical; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; H

1991
Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
    Progress in clinical and biological research, 1990, Volume: 350

    Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy;

1990
Adjuvant mitomycin-C prolongs survival time of patients undergoing extensive en bloc resection of carcinoma of the stomach invading the adjacent organs.
    Pharmacology, 1990, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Humans; Mitomycin; Mitomycins; Neoplasm

1990
[Retrospective study of short survival cases in hepatocellular carcinoma after transcatheter arterial embolization therapy].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:4

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Gelatin Sponge, Absorbable; Human

1985
[Treatment of gastric cancer based on the pathological and biophysiological aspects of cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:2

    Topics: Combined Modality Therapy; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Mitomycin

1986
Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
    British journal of urology, 1986, Volume: 58, Issue:6

    Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Ethoglucid; Humans; Methotrexate; Mitomy

1986
[Treatment of renal cell carcinoma invading the inferior vena cava; role of preoperative targeting chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:3 Pt 2

    Topics: Adult; Carcinoma, Renal Cell; Humans; Infusions, Intra-Arterial; Kidney Neoplasms; Male; Middle Aged

1987
Selecting initial therapy for bladder cancer.
    Cancer, 1987, Aug-01, Volume: 60, Issue:3 Suppl

    Topics: Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystoscopy; Doxorubicin; Human

1987
Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
    The Journal of urology, 1988, Volume: 140, Issue:2

    Topics: Administration, Intravesical; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell

1988
A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy.
    The Journal of urology, 1988, Volume: 140, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

1988
[A case of disappearance of peritoneal dissemination in gastric cancer induced by continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:8

    Topics: Ascitic Fluid; Cisplatin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged;

1988
Mitomycin C in superficial bladder cancer: 24-month follow-up.
    British journal of urology, 1985, Volume: 57, Issue:6

    Topics: Antibiotics, Antineoplastic; Carcinoma in Situ; Follow-Up Studies; Humans; Mitomycin; Mitomycins; Ne

1985